ERK_2在食管鳞状细胞癌组织中的表达及临床意义

目的研究ERK2在食管鳞状细胞癌组织中的表达及临床意义。方法应用免疫组化S-P法检测食管正常黏膜、癌旁组织及食管癌组织中ERK2表达状况。结果食管正常黏膜、癌旁组织及食管癌组织中ERK2表达率分别为20.0%(4/20)、45.7%(16/35)及86.2%(81/94),食管癌组织中ERK2表达率明显高于正常黏膜及癌旁组织组(P<0.05)。正常黏膜组和癌旁组织组ERK2表达率无明显差异(P>0.05),食管癌组织中ERK2表达与患者年龄、性别、肿瘤浸润深度、组织分化、淋巴结转移、临床分期及其它临床病理因素无关(P>0.05)。结论ERK2过表达在食管癌发生中起重要作用,单独检测ERK表达可能无助于判断患者的预后。     

突触融合蛋白6在食管鳞状细胞癌中的表达及临床意义

目的:探讨突触融合蛋白6(syntaxin 6,STX6)蛋白在食管鳞状细胞癌(esophageal squamous carcinoma,ESCC)组织中的表达及临床意义。方法:回顾性分析了241位食管癌病人的临床资料,应用免疫组织化学方法及Western blot法检测肿瘤组织和癌旁食管组织中STX6蛋白的表达情况,并进行统计分析,分析STX6的表达水平与各临床指标间的关系。结果:免疫组织化学法及Western blot结果均显示食管鳞状细胞癌组织中STX6的水平较临近的癌旁食管组织显著上升。食管癌患者病变组织中STX6的表达水平与性别、肿瘤分化程度、有无淋巴结转移以及肿瘤分期显著相关(P0.05),与患者的肿瘤大小、年龄没有明显的相关性(P0.05)。结论:STX6在食管癌的发生发展过程中起着重要的作用,是一个有价值的诊断及治疗靶点。     

MRP2 蛋白在食管鳞癌中的表达及其与化疗耐药的相关性

目的:探讨MRP2蛋白在食管鳞癌组织中的表达及其与食管癌化疗耐药的关系。方法:收集原发性食管鳞癌手术标本70例,采用免疫组织化学Envision法检测食管鳞癌组织及其癌旁组织中MRP2蛋白的表达情况,并采用MTT法检测食管鳞癌组织对临床常用化疗药物的敏感性,分析其表达与食管癌化疗耐药的关系。结果:70例食管鳞癌组织及其癌旁正常组织中的阳性表达率分别为58.6%及5.0%。MRP2蛋白在食管鳞癌组织中的阳性表达率明显高于癌旁正常食管组织(P<0.01)。食管鳞癌组织对环磷酰胺、5-氟尿嘧啶、吉西他滨、顺铂、卡铂、阿霉素、长春瑞滨、羟喜树碱等化疗药物的敏感性与其相应癌组织中MRP2表达明显相关(P<0.01)。结论:MRP2的表达与食管鳞癌对多种化疗药物耐药有较好的相关性,推测食管鳞癌组织中MRP2的高表达可能对化疗耐药性的发生发展具有促进作用。     

TYK2、RASSF1A与乳腺癌临床病理参数及预后相关性

[目的]研究TYK2、RASSF1A的表达与乳腺癌临床病理参数及预后的相关性。[方法]选择乳腺癌患者240例作为研究对象,比较患者的癌症组织与癌旁组织的TYK2、RASSF1A的表达差异,分析TYK2、RASSF1A的表达与乳腺癌临床病理参数及预后的相关性。[结果]癌症组织的TYK2阳性率(54.17%)显著高于癌旁组织(14.58%),癌症组织的RASSF1A的阳性率(15.83%)显著低于对照组(45.00%)(P<0.05);患者的肿瘤直径、TNM分期、淋巴结转移、脉管转移、ER情况、PR情况以及生存情况与患者的TYK2呈现正相关,与RASSF1A呈现负相关。[结论]TYK2的异常表达与乳腺癌临床病理参数及预后呈现正相关,RASSF1A的异常表达与乳腺癌临床病理参数及预后呈现负相关,临床可将TYK2和RASSF1A表达水平作为患者预后评估的重要依据。     

DNA修复酶MYH在食管鳞癌的表达和临床意义

目的:探讨食管鳞癌组织MYH的表达与8-oxoG氧化损伤和临床病理特征之间的关系。方法:用免疫组化染色和Western blot实验,比较食管鳞癌组织和癌旁组织MYH表达的高低;用免疫组化染色比较食管鳞癌组织和癌旁组织8-oxoG氧化损伤程度的高低。统计分析食管鳞癌组织MYH表达的高低与患者临床和病理特征的关系,采用x2检验。结果:食管鳞癌组织MYH蛋白表达低于其癌旁组织,食管鳞癌组织8-oxoG氧化损伤程度高于其癌旁组织。食管鳞癌组织MYH蛋白低表达,与该组织8-oxoG氧化损伤程度、浸润深度、静脉侵犯、TNM分期、淋巴结转移有关,与年龄、性别、病理分化程度无关。结论:食管鳞癌组织MYH蛋白低表达,可能与食管鳞癌的发展有关,后常规对患者食管癌标本做MYH表达的检测,可指导食管鳞癌术后化学治疗方案的制定。     

食管鳞癌组织中TNFAIP3的表达及其预后意义

目的研究肿瘤坏死因子α诱导蛋白3(tumor necrosis factorα-induced protein 3, TNFAIP3)在食管鳞癌中表达的临床病理意义及其对鳞癌预后的判断价值。方法免疫组织化学法检测100例随访食管鳞癌及80例癌旁组织中TNFAIP3蛋白的表达,并分析了其与食管鳞癌临床病理特征及预后的关系。结果 TNFAIP3在食管鳞癌中高表达阳性率为47.0%(47/100),显著高于癌旁组织中的高表达率15.0%(12/80),且与肿瘤的分化程度有关;生存分析显示高表达TNFAIP3的患者预后不良,单因素生存分析显示TNFAIP3的表达、肿瘤的浸润深度、淋巴结转移、临床分期与食管鳞癌预后密切相关,多因素生存分析显示TNFAIP3的表达、肿瘤的浸润深度、淋巴结转移、临床分期为食管鳞癌的独立预后预测因子。结论表达增高的TNFAIP3可能参与了食管鳞癌的发生发展,TNFAIP3的高表达可能成为食管鳞癌的独立预后因子。     

整合素alpha-v mRNA在食管鳞状细胞癌组织的表达研究

目的:检测食管鳞状细胞癌(Esophageal squamous cell carcinoma ESCC)组织整合素αv(integrinαv ITGA V)的表达,分析ITGA V表达与临床病理因素之间的相关性,探讨ITGA V在ESCC的进展和预后中的作用。方法:采用实时荧光定量PCR法检测72例ESCC组织ITGA V的表达,并同时检测33例食管炎性组织为对照。分析ITGA V表达与ESCC癌临床病理因素之间的相关性。结果:ESCC癌组织中ITGA V的m RNA表达水平明显高于炎症组织(P<0.05),且表达水平与T、N和临床分期(P均<0.05)呈显著相关,而与患者年龄及性别无相关性。结论:ITGA V的过度表达与ESCC的转移、进展有关,ITGA V可能会成为ESCC患者个体化治疗有效的预后标志物。     

Pokemon和MDM2在食管鳞癌组织中的表达及其临床意义

目的研究Pokemon及鼠双染色体2(MDM2)在食管鳞状细胞癌(ESCC)组织中的表达及临床意义。方法采用免疫组化法检测93例ESCC组织、30例癌旁正常黏膜组织(对照)中Pokemon及鼠双微染色体2(murine double minute 2,MDM2)蛋白的表达水平,分析Pokemon及MDM2蛋白表达与临床病理各参数之间的关系。结果 Pokemon在对照组织和ESCC中的阳性表达率分别为6.67%(2/30)和64.52%(60/93)(P0.01);MDM2在对照组织和ESCC中的阳性表达率分别为20%(6/30)和58.06%(54/93)(P0.01)。Pokemon蛋白表达水平与ESCC淋巴结的转移和临床病理分期呈正相关(P0.05),而与患者的年龄、性别、组织学分级和浸润深度等无相关(P0.05)。MDM2蛋白的表达与ESCC的组织学分级、淋巴结转移和临床分期呈正相关(P0.05),而与患者的年龄、性别、和浸润深度无相关性(P0.05)。Pokemon和MDM2在ESCC组织中呈正相关(r=0.508)。结论 Pokemon和MDM2的激活促进了ESCC的发生发展、浸润及转移。联合检测两基因的表达对深入了解食管癌的发展及转移机制具有重要意义。     

Cyclin D1, Bcl-2, P53和Survivin在丙型肝炎病毒相关肝细胞肝癌中 临床病理意义

目的:研究cyclin D1,bcl-2,p53和survivin在丙型肝炎病毒(hepatitis C virus,HCV)相关性肝细胞性肝癌(hepatocellular carcinoma,HCC)癌组织及癌旁组织中的表达,探讨其表达与丙型肝炎病毒相关性肝细胞性肝癌患者临床病理特征及生存预后之间的关系。方法:采用免疫组化检测方法检测cyclin D1,bcl-2,p53和survivin在丙型肝炎病毒相关性肝癌组织、癌旁组织和基本正常的肝组织中的表达,统计分析各因子的表达情况以及与患者临床病理特征的关系,并利用Kaplan-Meier分析法进一步分析各因子与患者生存预后之间的关系。结果:cyclin D1,bcl-2,p53和survivin在基本正常肝脏组织、癌旁组织和癌组织中的表达呈现递增的趋势,且cyclin D1,bcl-2,p53和survivin在癌组织的表达显著高于癌旁组织和基本正常的肝脏组织(P0.05);经统计学分析,cyclin D1,bcl-2和p53与肿瘤的分化程度相关(P0.05),而survivin与血管的浸润情况相关(P0.05);Kaplan-Meier分析显示,cyclin D1,p53和survivin与患者的不良预后有关(P0.05),而bcl-2与患者的不良预后无关(P0.05)。结论:cyclin D1,bcl-2,p53和survivin可能与丙型肝炎病毒相关性肝细胞性肝癌的发生存在一定的联系,除此之外,cyclin D1,p53和survivin与丙型肝炎病毒相关性肝细胞性肝癌患者的不良预后相关,而bcl-2与预后不存在显著相关性。     

EBP50和EGFR在食管癌中的表达和临床意义

为了探讨抑癌基因磷酸化蛋白(EBP50)和表皮生长因子受体(EGFR)在食管癌中的表达及临床预后关系,本研究采用免疫组化方法检测66例食管癌及癌旁组织中EBP50和EGFR蛋白的表达。研究发现,EBP50在食管癌组织中的表达低于癌旁正常食管组织(p0.05);EGFR在食管癌中的表达较癌旁正常食管组织上调(p0.05);EGFR高表达和EBP50低表达与食管鳞癌的大小、浸润、分期及淋巴结转移密切相关(p0.05);食管癌组织中EBP50与EGFR的蛋白表达呈负相关(r=0.969, p0.05),而联合EBP50低表达、EGFR高表达的患者存在比较差的预后(p0.05)。本研究表明,EBP50蛋白的低表达和EGFR蛋白的高表达可能参与了食管癌的发展、侵袭和转移的过程,可作为预测食管癌预后的重要指标。     

Stromal interaction molecule 1 promotes tumor growth in Esophageal squamous cell carcinoma

Esophageal squamous cell carcinoma (ESCC) is a disease with poor prognosis which urgently is in need of effective prognostic marker. To discover novel prognostic protein marker for ESCC, we applied a high-throughput monoclonal antibody microarray to compare tumor and adjacent non-tumor tissues from ESCC patients. Antibody #ESmAb270 was consistent higher expressed in tumors and it was identified via mass spectrometry to be stromal interaction molecule 1 (STIM1). STIM1 H scores in tumor tissues were significantly up-regulated in esophageal tumor tissues compared to non-tumor tissues in 105 ESCC patients. We also observed that high STIM1 expression was correlated with advanced tumor grade and poor prognosis of ESCC. In addition, attenuation of STIM1 by siRNA or chemical inhibitors significantly inhibited cell viability and migration of ESCC cells. Evidence from high-throughput monoclonal antibody microarray, IHC microarray with associated survival data and functional analysis show that STIM1 is an unfavorable prognostic biomarker in ESCC.     

长链非编码RNA BANCR在食管鳞癌中的表达及对细胞增殖和侵袭能力的影响

目的:探索长链非编码RNA BANCR与食管鳞癌(esophageal squamous cell carcinoma ESCC)临床病理特征以及预后的关系,以及对于ESCC细胞增殖,迁移和侵袭能力的影响。方法:使用实时荧光定量PCR(q RT-PCR)技术检测ESCC组织及多个细胞系中BANCR的表达水平,分析其与临床病理特征及预后的关联,用小干扰RNA(si RNA)干扰BANCR后用CCK8法检测其对ESCC细胞生长的影响,使用transwell法检测对细胞侵袭和转移能力的影响。结果:相对于癌旁组织,有86%(123/142)的癌组织中BANCR表达量升高,BANCR在癌组织中的相对表达水平与肿瘤的组织学分级、TNM分期和淋巴结转移数量相关(P均0.05)。BANCR在本文涉及的八株ESCC细胞中的表达量均高于正常食管上皮细胞(Het1A)。在TE10和KYSE30细胞中敲降BANCR后可明显降低细胞生长速率,并抑制细胞的侵袭和迁移能力(P0.01)。结论:BANCR在ESCC组织和细胞中表达显著上调。并能增强ESCC细胞的增殖和侵袭能力,有希望成为一种新的辅助ESCC早期诊断和预后判断的肿瘤分子标志物。     

Loss of 5-Hydroxymethylcytosine Is an Independent Unfavorable Prognostic Factor for Esophageal Squamous Cell Carcinoma

Ten-eleven translocation (TET) enzymes catalyze the oxidation of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), 5-formylcytosine and 5-carboxylcytosine, which result in genomic DNA demethylation. It was reported that 5-hmC levels were decreased in a variety of cancers and could be regarded as an epigenetic hallmark of cancer. In the present study, 5-hmC levels were detected by immunohistochemistry (IHC) in 173 esophageal squamous cell carcinoma (ESCC) tissues and 91 corresponding adjacent non-tumor tissues; DNA dot blot assays were used to detect the 5-hmC level in another 50 pairs of ESCC tissues and adjacent non-tumor tissues. In addition, the mRNA level of TET1, TET2 and TET3 in these 50 pairs of ESCC tissues was detected by real-time PCR. The IHC and DNA dot blot results showed that 5-hmC levels were significantly lower in ESCC tissues compared with corresponding adjacent non-tumor tissues (P = 0.029). TET2 and TET3 expression was also significantly decreased in tumor tissues compared with paired non-tumor tissues (TET2, P < 0.0001; TET3, P = 0.009), and the decrease in 5-hmC was significantly associated with the downregulation of TET2 expression (r = 0.405, P = 0.004). Moreover, the loss of 5-hmC in ESCC tissues was significantly associated with poor overall survival among patients with ESCC (P = 0.043); multivariate Cox regression analysis showed that the loss of 5-hmC in ESCC tissues was an independent unfavorable prognostic indicator for patients with ESCC (HR = 1.569, P = 0.029). In conclusion, 5-hmC levels were decreased in ESCC tissues, and the loss of 5-hmC in tumor tissues was an independent unfavorable prognostic factor for patients with ESCC.     

Pokemon、P14ARF 蛋白在食管鳞状细胞癌中的表达及临床意义

目的:探讨食管鳞癌(esophageal squamous cell cacinoma,ESCC)组织中Pokemon和P14ARF表达的关系及其对ESCC临床病理特征和预后的判定价值。方法:应用SP免疫组织化学方法检测Pokemon和P14ARF二种蛋白在96例ESCC组织及20例癌旁正常组织中的表达,分析它们与ESCC病理学特征的关系,以及Pokemon和P14ARF的相关性,并结合随访资料观察上述蛋白表达对ESCC长期预后的影响。结果:癌旁正常组织中未见Pokemon蛋白表达,P14ARF蛋白阳性表达率为90.0%;在ESCC组织中Pokemon和P14ARF阳性表达率分别为75.0%和30.2%。Pokemon表达与P14ARF表达呈负相关(r=-0.458,P=0.000)。Pokemon和P14ARF的表达与TNM分期和淋巴结转移相关(P<0.05)。Pokemon表达阳性组的5年生存率分别为20.8%,显著低于阴性组(P=0.004);P14ARF表达阳性组的5年生存率为41.4%,显著高于阴性组(P=0.011)。结论:Pokemon蛋白的高表达和P14ARF蛋白低表达可能与ESCC的发生、发展关系密切,它们对于ESCC预后评估有一定的临床意义。     

VEGF-A在食管鳞状细胞癌中的表达及临床意义

目的:探讨血管内皮生长因子A(VEGF-A)在食管鳞状细胞癌中的表达及临床意义。方法:收集2009年1月-2010年12月收治的45例食管鳞状细胞癌患者临床资料及病理标本,应用免疫组织化学法检测肿瘤组织VEGF-A表达及微淋巴管密度(MLVD),分析VEGF-A表达与食管鳞癌患者临床病理资料、MLVD及与患者生存期限的关系。结果:1有淋巴结转移的患者VEGF-A表达阳性率为66.67%,明显高于无淋巴结转移患者的38.10%(P0.05);2 VEGF-A阳性食管鳞状细胞癌患者MLVD为(8.35±2.45)明显高于阴性患者的(5.32±1.44),(P0.05);3VEGF-A阳性食管鳞状细胞癌患者3年存活率为41.67%明显低于阴性患者的61.90%(P0.05)。结论:VEGF-A表达在确定早期食管鳞状细胞癌淋巴结转移方面具有一定的应用价值,可以作为评价预后的有效指标。     

食管鳞状细胞癌中HDGF、VEGF表达与微血管形成的关系

目的:研究食管鳞状细胞癌中肝癌衍生生长因子(HDGF)、血管内皮生长因子(VEGF)的表达及其与微血管形成的关系。方法:通过免疫组化SABC法检测和比较68例食管鳞癌、20例切缘正常组织中HDGF、VEGF的表达和CD34标记的微血管密度(MVD),分析HDGF和VEGF表达之间的关系及其与食管鳞癌患者临床病理因素和食管癌组织MVD值的关系。结果:食管鳞癌组织中HDGF(63.2%)和VEGF(72.1%)的阳性表达率均明显高于切缘正常粘膜组织(15.0%、20.0%)(P0.05),食管鳞癌组织和切缘正常粘膜组织中的MVD值分别为35.48±5.75和13.50±2.1(P0.05)。食管鳞癌组织HDGF的阳性表达率仅与其临床分期明显相关(P0.05),而VEGF的阳性表达率与其淋巴结转移、临床分期均显著相关(P0.05),二者在食管鳞癌组织中的表达呈显著正相关(P0.05)。食管鳞癌组织中HDGF、VEGF阳性表达组MVD值均明显高于HDGF、VEGF阴性表达组(P0.05)。结论:HDGF可能通过诱导VEGF的产生,从而促进血管生成,参与食管鳞癌的发生、发展及转移。     

Tenascin-C,a Prognostic Determinant of Esophageal Squamous Cell Carcinoma

Background

Tenascin-C, an adhesion modulatory extracellular matrix molecule, is highly expressed in numerous human malignancies; thus, it may contribute to carcinogenesis and tumor progression. We explored the clinicopathological significance of Tenascin-C as a prognostic determinant of esophageal squamous cell carcinoma (ESCC).

Methods

In ESCC patient tissues and cell lines, the presence of isoforms were examined using western blotting. We then investigated Tenascin-C immunohistochemical expression in 136 ESCC tissue samples. The clinical relevance of Tenascin-C expression and the correlation between Tenascin-C expression and expression of other factors related to cancer-associated fibroblasts (CAFs) were also determined.

Results

Both 250 and 350 kDa sized isoforms of Tenascin-C were expressed only in esophageal cancer tissue not in normal tissue. Furthermore, both isoforms were also identified in all of four CAFs derived from esophageal cancer tissues. Tenascin-C expression was remarkably higher in ESCC than in adjacent non-tumor esophageal epithelium (p < 0.001). Tenascin-C expression in ESCC stromal fibroblasts was associated with patient’s age, tumor (pT) stage, lymph node metastasis, clinical stage, and cancer recurrence. Tenascin-C expression in cancer cells was correlated with an increase in tumor-associated macrophage (TAM) population, cancer recurrence, and hypoxia inducible factor1α (HIF1α) expression. Moreover, Tenascin-C overexpression in cancer cells and stromal fibroblasts was an independent poor prognostic factor for overall survival (OS) and disease-free survival (DFS). In the Cox proportional hazard regression model, Tenascin-C overexpression in cancer cells and stromal fibroblasts was a significant independent hazard factor for OS and DFS in ESCC patients in both univariate and multivariate analyses. Furthermore, Tenascin-C expression in stromal fibroblasts of the ESCC patients was positively correlated with platelet-derived growth factor α (PDGFRα), PDGFRβ, and smooth muscle actin (SMA) expression. The 5-year OS and DFS rates were remarkably lower in patients with positive expressions of both Tenascin-C and PDGFRα (p < 0.001), Tenascin-C and PDGFRβ (p < 0.001), Tenascin-C and SMA (p < 0.001), Tenascin-C and fibroblast activation protein (FAP) (p < 0.001), and Tenascin-C and fibroblast-stimulating protein-1 (FSP1) (p < 0.001) in ESCC stromal fibroblasts than in patients with negative expressions of both Tenascin-C and one of the abovementioned CAF markers.

Conclusion

Our results show that Tenascin-C is a reliable and significant prognostic factor in ESCC. Tenascin-C may thus be a potent ESCC therapeutic target.     

A Relationship Between Replication Protein A and Occurrence and Prognosis of Esophageal Carcinoma

Esophageal carcinoma (EC) is an aggressive and the third most common cancer of the digestive tract with poor prognosis. Replication protein A (RPA) is critically required for DNA replication and its elevated expression has been observed in many malignant tumors. In this study, we investigated the expression of RPA1 and RPA2, subunits of RPA, and assessed their prognostic value in EC patients. We analyzed immunohistochemically the expression of RPA1 and RPA2 proteins in 48 EC resection specimens in relation with clinicopathological parameters and survival. We observed a significant elevated (P < 0.001) RPA1 and RPA2 expressions (labeling index) in the tumor than adjacent non-tumor tissues. In addition, both RPA1 and RPA2 labeling index in lymph node metastasis patients was significantly higher (both P = 0.000) than patients without lymph node metastasis. However, RPA1 and RPA2 labeling index in early stage was significantly lower (P = 0.000 and P = 0.002, respectively) than that of late stage EC patients. Importantly, patient’s survival at early stage was significantly higher (P = 0.016) than late stage EC and lymph node metastasis and RPA1 expression was associated with adverse patient’s outcome in multivariate analysis (P < 0.05 and P < 0.00, respectively). In conclusion, RPA1 could be a useful prognostic indicator in patients with esophageal carcinoma and might be a future attractive therapeutic target for regulation by tumor suppressors.     

JMJD6在胃癌组织中的表达及意义

目的:检测JMJD6蛋白在胃癌组织及相应癌旁正常组织中的表达情况,并分析JMJD6蛋白表达与胃癌患者临床病理参数及预后的关系。方法:应用免疫组织化学方法检测JMJD6蛋白在胃癌组织及相应癌旁正常组织中的表达情况,进一步用Kaplan-Meier生存分析、COX比例风险回归模型等统计学方法研究JMJD6表达与胃癌患者临床病理参数及预后的关系。结果:JMJD6在胃癌组织中的表达阳性率显著高于癌旁正常组织(P=0.001);JMJD6在胃癌组织的高表达与肿瘤临床分期(P=0.008)、病理分级(P=0.001)、局部浸润深度(P=0.028)、有无淋巴结转移(P=0.001)等显著相关;Kaplan-Meier生存分析结果表明JMJD6高表达的胃癌患者术后总体生存率显著低于JMJD6低表达的患者(P=0.023)。结论:JMJD6在胃癌的发生发展中可能发挥了癌基因样作用,可能作为胃癌治疗的潜在靶点。     

食管鳞癌血管生成拟态的组织学和细胞学研究

目的:探讨血管生成拟态(vasculogenic mimicry,VM)与食管鳞癌临床病理特征的关系及其对患者预后的影响,并分析食管癌血管生成拟态的形成机制。方法:收集57例食管鳞癌石蜡包埋样本,进行过碘酸雪夫氏(PAS)及CD34免疫组织化学双重染色,结合HE染色,观察食管鳞癌血管生成拟态的发生情况。对患者临床病理和预后信息进行单因素分析,Kaplan-Meier生存比较和Cox风险模型分析。通过食管鳞癌细胞株Eca-109三维培养建立,观察RNAi沉默VE-cadherin对食管鳞癌Eca109血管生成拟态形成的影响。结果:食管鳞癌中VM表达的阳性率为54.3%,显著高于正常食管黏膜组织;VM在病理分型为低分化食管鳞癌的阳性表达率为78.9%,显著高于中高分化组(P0.05);III-Ⅳ期食管鳞癌患者VM阳性率显著高于Ⅰ-Ⅱ期食管鳞癌患者(P0.05);有淋巴结转移的食管鳞癌者VM阳性率明显高于无淋巴结转移者(P0.05)。单因素分析结果显示食管鳞癌VM的发生率与肿瘤的分化程度、TNM分期和淋巴转移显著相关。Kaplan-Meier生存分析显示有VM组食管鳞癌患者的生存期明显短于无VM组(P0.05);Cox分析显示VM是影响食管鳞癌患者预后的独立危险因素(RF=0.67)。三维培养结果显示Eca-109细胞在基质胶上形成典型的血管网状样结构,VE-cadherin-siRNA可有效抑制VE-cadherin在Eca109的表达,抑制体外培养的Eca109细胞VM的形成。结论:血管生成拟态是食管鳞癌一种独特的血液供应模式,与食管鳞癌的分化程度、TNM分期、淋巴转移密切相关,是食管鳞癌患者术后生存期的独立危险因素。